Precipitation of soluble uric acid is necessary for in vitro activation of the NLRP3 inflammasome in primary human monocytes by Alberts, Ben et al.
Precipitation of soluble uric acid is necessary for in vitro 
activation of the NLRP3 inflammasome in primary human 
monocytes
Article  (Accepted Version)
http://sro.sussex.ac.uk
Alberts, Ben, Barber, James, Sacre, Sandra, Davies, Kevin, Ghezzi, Pietro and Mullen, Lisa 
(2019) Precipitation of soluble uric acid is necessary for in vitro activation of the NLRP3 
inflammasome in primary human monocytes. The Journal of Rheumatology. ISSN 1499-2752 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/80915/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
1 
 
Precipitation of Soluble Uric Acid is Necessary for in vitro Activation of the NLRP3 Inflammasome 
in Primary Human Monocytes 
Author information: 
Mr Ben M Alberts.  ORCID iD: 0000-0002-3574-3176  
Mr James S Barber. ORCID iD: - 
Dr Sandra M Sacre.  ORCID iD: 0000-0003-1665-1142  
Professor Kevin A Davies. ORCID iD: -  
Professor Pietro Ghezzi. ORCID iD: 0000-0003-0911-8358 
Dr Lisa M Mullen. ORCID iD: 0000-0001-8278-2226 
Key indexing terms: Inflammasomes, Inflammation, Gout, Uric Acid, Monocytes, Reactive Oxygen 
Species. 
Department and institution: Brighton and Sussex Medical School, University of Sussex, Brighton, UK, 
BN1 9PS 
Source of support: This work was supported by Brighton and Sussex Medical School. 
Conflict of interests: The authors have declared no conflicts of interest 
Authors:  
Mr B M Alberts, PhD Student, BSc. 
Mr J S Barber, MBBS. 
Dr S M Sacre, Senior Lecturer in Molecular Cell Biology, PhD.  
Professor K A Davies, Head of the Department of Clinical and Experimental Medicine, PhD.  
Professor P Ghezzi, RM Phillips Chair in Experimental Medicine, PhD.  
Dr L M Mullen, Lecturer in Biochemistry, PhD.  
Corresponding author: Dr Lisa M Mullen. Medical Research Building, University of Sussex, Brighton, 
BN1 9PS. L.Mullen@bsms.ac.uk  
Short running head: Hyperuricemia and NLRP3 Activation   
2 
 
Abstract: 
Objective. To investigate the effects of soluble uric acid (UA) on expression and activation of the NOD-
like receptor (NLR) pyrin domain containing protein 3 (NLRP3) inflammasome in human monocytes to 
elucidate the role of hyperuricemia in the pathogenesis of gout.  
Methods. Primary human monocytes and the THP-1 human monocyte cell line were used to 
determine the effects of short- and long-term exposure to UA on activation of the NLRP3 
inflammasome and subsequent interleukin-1β (IL-1β) secretion by enzyme linked immunosorbent 
assay (ELISA) and cell-based assays. Expression of key NLRP3 components in monocytes from patients 
with a history of gout were analysed by quantitative PCR.  
Results. Precipitation of UA was required for the activation of the NLRP3 inflammasome and 
subsequent release of IL-1β in human monocytes. Neither monosodium urate (MSU) crystals nor 
soluble UA had any effect on activation of the transcription factor, NF-κB. Prolonged exposure of 
monocytes to soluble UA did not alter these responses. However, both MSU crystals and soluble UA 
did result in a 2-fold increase in reactive oxygen species (ROS). Gout patients (n=15) had significantly 
elevated serum UA concentrations compared to healthy individuals (n=16), yet secretion of IL-1β and 
expression of NLRP3 inflammasome components in monocytes isolated from these patients were not 
different from healthy controls.  
Conclusion. Despite recent reports indicating that soluble UA can prime and activate the NLRP3 
inflammasome in human peripheral blood mononuclear cells (PBMCs), precipitation of soluble UA into 
MSU crystals is essential for in vitro NLRP3 signalling in primary human monocytes.  
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Introduction 
Uric acid (UA) is a major antioxidant in the plasma that can help protect against free-radical induced 
oxidative stress. Indeed, this function of UA is thought to have led to the evolutionary loss of the 
uricase gene in humans resulting in much higher circulating concentrations of UA in humans than in 
other mammals (1, 2). Clinically relevant hyperuricemia is defined as a plasma UA concentration in 
excess of 6.8 mg/dL (3) which is at increased risk of precipitation to form potentially pro-inflammatory 
monosodium urate (MSU) crystals (4). 
Hyperuricemia is associated with a number of pathological conditions including metabolic syndrome 
(5), hypertension (6), chronic kidney disease (7) and cardiovascular disease (8). It is also the biggest 
single risk factor for gout, the pathophysiology of which is primarily driven by the production of the 
pro-inflammatory cytokine IL-1β released as a result of recognition of MSU crystals by mononuclear 
cells (9). Intriguingly, only about 10% of hyperuricaemic individuals ever develop gout (10), nor does 
the presence of MSU crystals within joints necessarily precipitate a gout attack (11). 
In vivo processing and subsequent secretion of IL-1β occurs via activation of the NOD-like receptor 
(NLR) pyrin domain containing protein 3 (NLRP3) inflammasome. This is a tripartite cytosolic complex 
formed of three proteins NLRP3, Apoptosis-associated Speck-like protein containing a CARD domain 
(ASC) and pro-caspase-1. Upon activation, NLRP3 oligomerises with the adaptor protein ASC which in 
turn mediates the recruitment of the inactive zymogen pro-caspase-1 (12). Oligomerisation of 
inflammasome components ultimately results in the autoproteolytic cleavage of pro-caspase-1 into 
its active form. Caspase-1 then cleaves pro-IL-1β and pro-IL-18 into their active forms resulting in their 
secretion from cells (13).   
It is generally accepted that activation of the NLRP3 inflammasome requires two distinct signals, 
although an alternative pathway has recently been identified in human monocytes in response to LPS 
(14). These two signals consist of a priming signal to induce transcription of both NLRP3 and pro-IL-
1β, and a second signal that induces oligomerisation of the inflammasome. Various ligands can induce 
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NLRP3 priming, including the toll-like receptor (TLR) 2 ligand Pam3CSK4 (Pam3) and the TLR4 ligand 
lipopolysaccharide (LPS) via activation of NF-κB (15). A number of structurally diverse stimuli can 
function as the second signal but none have been demonstrated to interact directly with 
inflammasome proteins (16, 17). Possible mechanisms by which second signals activate the 
inflammasome include lysosomal degradation(18), cationic flux(19) and generation of reactive oxygen 
species (ROS) (20). 
Despite hyperuricemia being the single greatest risk factor for the development of gout, the precise 
role of UA in its pathophysiology remains to be fully elucidated. Recent studies have shown that 
soluble UA can influence both the priming and activation of the inflammasome even in the absence 
of MSU crystal formation (21-23). However, many of these studies were completed in human PBMCs 
or mouse bone marrow derived macrophages which may not accurately reflect the responses of 
primary human monocytes.  
It is important to fully define the role of UA in activating the NLRP3 inflammasome in these cells, as 
monocytes rather than PBMCs are the major producers of IL-1β during an acute attack of gout (24).  
Thus, the aim of this study was to determine the effect of soluble UA on activation of NLRP3 in human 
monocytes to investigate how hyperuricemia can increase susceptibility to gout at the cellular level. 
We used a combination of human monocytic THP-1 cells and primary human monocytes from healthy 
controls and gout patients to investigate both the acute and longer-term effects of UA on expression, 
priming and activation of the NLRP3 inflammasome.  
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Materials and Methods 
Reagents  
Cell culture media, fetal bovine serum (FBS), and uric acid were purchased from Sigma-Aldrich (St 
Louis, MO). Opti-MEM media and penicillin/streptomycin were purchased from Thermo Fisher 
Scientific (East Grinstead, UK). MSU crystals, MCC950(25)  and QUANTI-Blue reagent were purchased 
from Invivogen (San Diego, CA). Qiazol, QuantiTect Reverse Transcription kit, QuantiFast-SYBR green 
PCR kit were from Qiagen (Hilden, Germany).  
Ethical approval 
National Research Ethics Service approval (NRES reference: 15/NS/0083) was obtained for collection 
of human blood samples after receiving informed written consent. No patient identifiable information 
was ever accessed by researchers. For purchased blood products, local ethical approval was given by 
the Brighton and Sussex Medical School Research Governance and Ethics Committee (R&D REF 
number: 15/130/MUL).  
Isolation and stimulation of primary human monocytes  
Single donor plateletphoresis residues were obtained from the North London Blood Transfusion 
Centre (United Kingdom). PBMCs were isolated by density gradient separation using lympholyte-H cell 
separation media (VH Bio, UK)  followed by isolation of monocytes by Percoll (Sigma-Aldrich, MO) 
density gradient centrifugation (26). Cells were stored in liquid nitrogen for future use.  
The appropriate concentration of MSU crystals for stimulating cells was determined by titration to 
achieve activation of NLRP3 with no effects on viability (data not shown). Soluble UA concentrations 
were chosen to allow direct comparison with MSU crystal concentrations and were subsequently 
increased to represent a wider range of hyperuricemia. UA was dissolved in pre-warmed RPMI at a 
final concentration of 0.6-1.0 mg/ml and filter sterilized using 0.20 µm filters. Crystals were not 
detectable in preparations of uric acid, nor were crystals ever observed under any of the experimental 
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conditions used (Supplementary Fig. 1). For experiments, monocytes were resuspended in RPMI cell 
culture media containing 5% FCS and seeded at 3 x 105 cells/well in 96-well plates. For experiments 
involving pre-incubation of cells with soluble UA, cells were allowed to adhere for 2 hours and then 
incubated in RPMI (5% FCS) -/+ 30mg/dL UA for 10-16 hours. Cells were then washed with RPMI and 
stimulants added for the specified time.  
For some experiments, monocytes were isolated from 30 mL of blood collected from gout patients 
(n=15) or healthy volunteers (n=16). Gout patients were defined as those who had suffered an 
inflammatory arthritic attack that was clinically diagnosed as gout. The majority of these patients 
(10/16) were prescribed anti-inflammatory medication, with 50% prescribed allopurinol. PBMCs were 
isolated by density gradient separation using lympholyte-H followed by purification of monocytes 
using CD14+ magnetic bead (Miltenyi Biotec, Germany) positive isolation and stored in liquid nitrogen 
until use. Matched serum samples were collected from each donor and stored at -80 °C. For 
experiments, cells were seeded at 4 x 104 cells/well in 384-tissure culture plates and allowed to adhere 
for 2 hours, then stimulated for 18 hours in culture media containing Pam3 +/- MSU.  
Culture and stimulation of THP-1 cells  
The human THP-1 monocytic cell line was cultured in RPMI-1640 media supplemented with 10% (v/v) 
FCS and streptomycin/penicillin (100 µg/mL and 100 U/mL, respectively). THP-1 cells were seeded at 
1.6 x 105 cells/well in 96-well plates and stimulated for 18 hours with Pam3, UA or MSU before 
collecting cell conditioned media for analyses. The THP1-Blue cell line (Invivogen, Toulouse, France) is 
derived from human THP-1 monocytes with stable integration of an NF-κB-inducible secreted 
embryonic alkaline phosphatase (SEAP) reporter construct and cultured as described for THP-1 cells 
with the addition of 100 µg/mL of Zeocin to maintain the reporter plasmid. For experiments requiring 
preincubation with UA, cells were cultured in the presence of 30 mg/dL of UA in complete RPMI for 
24-48 hours and then seeded and stimulated for the specified times.  
Measurement of NF-κB activation in THP-1 Blue cells 
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THP1-Blue cells were stimulated for 20 hours with 100 ng/mL Pam3, 10-40 mg/dL UA and/or 10-20 
mg/dL of MSU crystals. SEAP levels were determined using Quanti-Blue assay (Invivogen) according to 
the manufacturer’s instructions.  
Quantification of IL-1β  
IL-1β in cell supernatants was measured by ELISA using matched anti-human IL-1β antibodies (R&D 
systems).   
ROS measurements 
ROS generation was detected using ROS-Glo assay (Promega) according to the manufacturer’s 
instructions (27). Briefly, cells were stimulated for 2 hours with 100 ng/mL Pam3, 10 mg/dL of MSU or 
30 mg/dL of UA in the presence of 25 µM ROS-Glo H2O2 substrate and ROS levels determined by the 
addition of ROS-Glo detection reagent. Luminescence was measured by spectrophotometry. 
Measurement of serum uric acid  
Serum UA concentrations were measured using an Amplex Red-based uric acid/uricase assay kit 
(ThermoFisher) according to the manufacturer’s instructions. Fluorescence of Amplex red reagent was 
measured at ex530/em590nm. 
RNA extraction, reverse transcription and absolute RT-qPCR 
Monocytes were washed twice in PBS, then RNA extracted using RNeasy kits (Qiagen) and reverse 
transcribed to cDNA using QuantiTect reverse transcription kits (Qiagen, UK) according to the 
manufacturer’s instructions. The qPCR assays for absolute quantification of gene expression were 
purchased from qStandard (London, UK). Copy numbers for NLRP3, CASP1, IL1β and PYCARD (gene 
name for ASC) were determined by Quantitative real-time RT-PCR (qPCR) using the QuantiFast SYBR 
Green PCR kit (Qiagen) on a Stratagene Mx3000 thermocycler (Agilent Technologies, UK) or Rotor-
Gene thermocycler (Qiagen, Germany) under the following thermocycling program; 40 cycles of 95°C 
for 15 seconds and 60°C for 30 seconds with an initial cycle of 95°C for 15 minutes. The following 
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primers were used; human Beta-2 Microglobulin (B2M), forward 5’-ctctctctttctggcctggag-3’ and 
reverse 5’-acccagacacatagcaattcag-3’; human ribosomal protein L32 (RPL32), forward 5’-
catctccttctcggcatcat-3’ and reverse 5’-accctgttgtcaatgcctct-3’; human CASP1, forward 5’-
atgcctgttcctgtgatgtgg-3’ and reverse 5’-ctcttcacttcctgcccacaga-3’; human IL1B, forward 5’-
gtaatgacaaaatacctgtggccttg-3’ and reverse 5’-tttgggatctacactctccagc-3’; human NLRP3, forward 5’-
gagatgagccgaagtggggttc-3’ and reverse 5’-gcttctcacgtactttctgtacttct-3’; human PYCARD, forward 5’-
gctaacgtgctgcgcgacat-3’ and reverse 5’-ccactcaacgtttgtgaccct-3’. Copy number for each gene of 
interest (GOI) and reference gene was calculated by interpolation from a standard curve ranging from 
101-107 copies run on the same plate. β2M and RPL32 were used as reference genes. 
Statistical analysis 
Differences between groups were assessed using unpaired t-tests, Mann-Whitney U-tests or one-way 
analysis of variance (ANOVA) followed by Tukey’s multiple comparison test after testing for 
differences in variation using the Brown-Forsythe test. Correlation analysis was performed using 
Pearson’s correlation coefficient. The level of significance was set at P < 0.05. All analyses were 
conducted using GraphPad Prism version 7 (Graphpad software, San Diego, CA). 
 
Results 
Effect of MSU and soluble UA on activation of the NLRP3 inflammasome in human monocytes 
THP-1 monocytes or primary human monocytes were used to investigate activation of the NLRP3 
inflammasome in response to MSU crystals or soluble UA. The TLR2 ligand, Pam3, was used as a 
priming signal and secretion of IL-1β used as a measure of NLRP3 activation. To confirm the activation 
of NLRP3, cells were stimulated in the presence of MCC950, a chemical inhibitor of NLRP3. In both 
THP-1 monocytes (Supplementary Fig. 2A) and primary human monocytes (Supplementary Fig. 2B) 
MCC950 inhibited IL-1β secretion in response to MSU crystals by 90%, confirming NLRP3-dependant 
secretion. Small increases in secretion of IL-1β were observed in response to Pam3 alone, with 
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significantly greater release of IL-1β in the presence of MSU in both THP-1 monocytes (Fig. 1A) and 
primary human monocytes (Fig. 1C). In contrast, addition of soluble UA did not increase Pam3-induced 
IL-1β secretion in either THP-1 cells (Fig. 1B) or primary human monocytes (Fig. 1D).  THP-1 Blue cells 
were used to investigate whether MSU or soluble UA had any effect on priming of the NLRP3 pathway. 
Neither MSU (Fig. 1E) nor soluble UA (Fig. 1F) treatment alone had any effect on activation of NF-κB 
in these cells, although the higher concentration of MSU did increase Pam3-induced NF-κB.  
In hyperuricemic individuals, circulating monocytes are exposed to elevated concentrations of soluble 
UA for prolonged periods. We therefore hypothesised that monocytes exposed to soluble UA prior to 
stimulation could have altered priming and activation of the NLRP3 inflammasome. To test this, 
primary human and THP-1 monocytes were exposed to soluble UA (30 mg/dL) for up to 48 hours. This 
concentration of soluble UA is well in excess of the accepted range for hyperuricaemia (>6.8 mg/dL). 
Longer incubation times were tested in THP-1 cells compared with primary human monocytes due to 
decreases in viability in primary cells after 24 hours culture. Pre-incubation of primary human 
monocytes with soluble UA for 10 hours (Fig. 2A), or THP-1 cells for up to 24-48 hours (Fig. 2B&C) had 
no effect on the release of IL-1β from these cells. Furthermore, activation of NF-κB in response to 
Pam3 +/- MSU was also unaffected by pre-incubation with soluble UA for 24 hours (Supplementary 
Fig. 3A&B) or 48 hours (Fig. 3D&E).   
Induction of ROS by soluble uric acid and MSU crystals in primary human monocytes 
To assess whether MSU crystals or soluble UA can induce ROS generation, we measured ROS levels in 
human monocytes. Initial experiments were done using catalase to decrease ROS or MSU to increase 
ROS to confirm that the ROS-Glo assay could indeed measure changes in ROS (Fig. 3A) and to 
determine the optimal timing for measurement of ROS in these cells (Fig. 3B). Short-term (2h) 
treatment with both MSU and soluble UA increased ROS generation in primary human monocytes (Fig. 
3C), an effect which was not seen when cells were pre-incubated with 30 mg/dL of soluble UA for 16 
hours prior to stimulation with Pam3 +/- MSU or UA (Fig. 3D).  
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Activation of the NLRP3 inflammasome in monocytes isolated from gout patients 
Susceptibility to gout attacks could be related to increased cellular sensitivity to MSU crystals. To test 
this hypothesis, monocytes were isolated from the blood of individuals with a previous history of gout 
attacks and stimulated for 18 hours with Pam3 +/- MSU crystals. Serum UA concentration was 
significantly higher in patients with gout (n=15) compared to healthy controls (n=16) (Fig. 4A), 
although only 27% of the subjects with gout were clinically hyperuricemic at the time of sampling.  
There were no significant differences in IL-1β secretion between monocytes from gout patients and 
healthy controls (Fig. 4B and C), although there was a trend towards increased responsiveness to MSU 
in monocytes from gout patients when the IL-1β secretion data was normalised to secretion induced 
by Pam3 alone for each donor (Fig. 4D). However, IL-1β secretion from these cells did not correlate 
with serum uric acid concentration (Supplementary Fig. 4). To determine whether this trend could be 
explained by increased expression of genes coding for components of the NLRP3 inflammasome, qPCR 
was used to determine constitutive expression levels of caspase-1 (CASP1), pro-IL-1β (IL1B), ASC 
(PYCARD) and NLRP3 in the absence of a stimulus. There were no differences in the expression of any 
of the genes tested between healthy controls and gout patients (Fig. 5A-D). Caspase-1 and pro-IL-1β 
transcripts were expressed at 10-fold greater levels than the NLRP3 transcripts. Finally, there was no 
correlation between serum UA concentration and expression of the inflammasome genes measured 
(Fig. 5D-F) in either healthy controls or gout patients.  
Discussion 
There are a limited number of studies assessing the effects of uric acid in primary human cells but the 
available data suggests that any effect of UA is cell-type specific and much more subtle than the well-
documented effects of crystallized UA. Thus, UA had no effect on release of IL-1β or TNF from human 
monocyte-derived macrophages but at concentrations of 50 mg/dL did induce secretion of IL-1β from 
PBMCs (22). However, these results were not recapitulated in monocytes where incubation with UA 
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had no effect on IL-1β similar to the results shown here, but did increase IL-1β production when cells 
were subjected to stimulation with LPS -/+ MSU after the initial incubation with UA (23).   
Clearly, the responses of isolated monocytes are different to those of PBMCs, which is a mixed 
population of monocytes and lymphocytes and contain on average approximately 8-10% of 
monocytes. The differences in responses to uric acid between human monocytes and PBMCs cannot 
be explained simply by differences in expression of NLRP3 as this is substantially lower in lymphocytes 
than in monocytes (28). However, is has previously been shown that UA can activate T cells in an 
antigen-independent manner (29). Perhaps there are interactions between activated T cells and 
monocytes that cause the monocytes in the PBMC mixture to respond to UA by secreting IL-1β, an 
effect not seen in pure monocyte cultures. This possibility deserves further investigation as it may 
provide important insights into the activation of monocytes during hyperuricemia.  
The monocytes from gout patients studied here showed a tendency to produce more IL-1β as a result 
of treatment with MSU. Serum UA concentration was higher in gout patients than in healthy donors 
and could indicate that constant exposure to UA may predispose monocytes to produce more IL-1β 
upon stimulation, a theory supported by previous studies conducted with PBMCs (22, 30).  However, 
despite the trend for increased responsiveness to Pam3 + MSU in the monocytes from gout patients 
observed here, this was not mirrored by increases in the levels of gene expression of components of 
the NLRP3 inflammasome nor did these levels correlate with serum uric acid concentration.  These 
data suggest that there are sufficient levels of NLRP3 inflammasome components at the protein level 
to allow secretion of IL-1β in the absence of upregulated gene expression. Importantly, it also suggests 
that exposure of monocytes to uric acid does not result in increased gene expression, perhaps 
explaining why hyperuricemia alone is insufficient to cause IL-1β-mediated inflammation.  
Increased expression of NLRP3, PYCARD, CASPASE-1 and IL-1β does occur in conditions such as  
atherosclerosis (31), Sjögren’s syndrome (32) and preeclampsia (33),  so it is intriguing that we found 
no increases in basal expression of these genes in gout patients, given the importance of IL-1B in the 
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disease process in gout. Of note, expression of NLRP3 was relatively low compared to both IL-1B and 
CASP1 consistent with the requirement for TLR-induced transcriptional priming and translation of 
NLRP3 prior to oligomerization and activation of the NLRP3 inflammasome (15).  
The increased ROS in response to UA in the monocytes studied here was intriguing, given the well-
known antioxidant effects of UA (34). However, UA is also known to have pro-oxidant effects 
depending on context and location, functioning as a pro-oxidant in intracellular spaces and as an anti-
oxidant in the extracellular environments (35). This raises the question of whether UA enters the 
monocytes over the course of the incubations or whether UA is exerting these effects on ROS by 
influencing the extracellular redox environment. Longer incubations with UA did not result in 
increased ROS in the cells and this could have been due to increases in cellular anti-oxidant activity as 
a compensatory measure. It is currently unclear whether or not UA can enter monocytes. UA is taken 
up by adipocytes (36) and VSMCs (37) via specific urate transporters and UA entry into these cell types 
results in increased ROS. Leukocytes do express the Glut9a urate transporter (38) that is associated 
with regulation of plasma urate levels, but there are no available data on whether Glut9a actually 
transports UA in these cells. 
The fact that we see increased ROS in monocytes upon incubation with UA, together with the 
epigenetic changes that occur in monocytes incubated with UA (22) could point to intracellular effects 
of UA in these cells. However, both of these observed effects could also be mediated by UA-induced 
changes in the extracellular environment that causes changes in the redox state of membrane 
receptors/proteins that then exert intracellular effects.  
The increases in ROS observed after incubation with UA did not influence IL-1β secretion, suggesting 
that ROS are dispensable for activation of the NLRP3 inflammasome. The role of ROS in IL-1β 
production is controversial, with some studies showing that activation of the NLRP3 inflammasome is 
reliant on ROS (39, 40), but others showing that ROS are dispensable in this process (19, 41, 42). Thus, 
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our findings are in agreement with the view that ROS are not involved in IL-1β production in 
monocytes. 
Our results are consistent with previously published work showing that incubation of primary human 
monocytes with UA did not result in IL-1β secretion (23). We did not see any effect of UA on 
subsequent stimulation of cells with Pam3 -/+ MSU as shown by others (23) because we only 
performed these experiments in THP-1 cells. The mechanism by which pre-incubation with UA 
increases IL-1β secretion upon subsequent stimulation with Pam3 is via downregulation of IL-1Ra 
which allows increased binding of the IL-1β produced to the IL-1R (22). Crucially, THP-1 cells do not 
express the IL-1R (43) and so cannot respond to IL-1β in this manner. Thus, any downregulation of IL-
1Ra in response to UA has no effect in our assays.    
What then is the relationship between hyperuricaemia and susceptibility to gout? There was no 
correlation between serum UA and production of IL-1β in monocytes from gout patients and our 
results also appear to demonstrate that crystallisation of UA into MSU is necessary for activating the 
NLRP3 inflammasome in these cells. One possibility is that hyperuricaemia results in higher levels of 
oxidative stress where there are greater levels of ROS than can be dealt with via antioxidant 
mechanisms. The relationship between oxidative stress and inflammation is complex, but these two 
states tend to potentiate each other (44, 45). It may be that there are less efficient antioxidant 
mechanisms operating in gout patients than in asymptomatic hyperuricaemic individuals resulting in 
higher levels of oxidative stress that could contribute to greater sensitivity to the existence of MSU 
crystals. As the presence of MSU crystals within joints does not always result in a gout attack it may 
be the case that a second trigger, perhaps increased oxidative stress, is required to activate the NLRP3 
inflammatory cascade. Indeed, this may also explain the association between gout and metabolic 
syndrome which is also characterised by increased oxidative stress and increased inflammation (46). 
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Figure legends: 
Figure 1. Priming and activation of the NLRP3 inflammasome in human monocytes. THP-1 (A&B) or 
primary human monocytes (C&D) were stimulated for 18 h with Pam3 ± MSU crystals or soluble UA. 
IL-1β secretion was determined by ELISA. THP1-blue monocytes (E&F) were stimulated for 20 h with 
Pam3, soluble UA or MSU crystals. NF-κB activation was determined via QUANTI-Blue assay. Data 
represents means from 3-4 separate experiments (THP-1 and THP1-Blue cells) or 3-5 individual donors 
(primary monocytes) ± S.E.M. Significance determined by one-way ANOVA or unpaired t-test (A&B) 
(*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). 
Figure 2. Effect of pre-incubation with soluble UA on priming and activation of NLRP3 in human 
monocytes. (A) Primary human monocytes were incubated with RPMI or soluble UA (30mg/dL) for 10 
h prior to treatments indicated for 12 h. THP-1 monocytes were incubated with soluble UA for 24 h 
(B) or 48 h (C) prior to indicated treatments for 18 h. IL-1β secretion was determined by ELISA. THP1-
Blue monocytes were pre-exposed to RPMI or soluble UA for 48 hours (D&E), followed by 20 h 
stimulation. NF-κB activation was determined via QUANTI-Blue assay. Data represent means ± S.E.M 
for 4 separate donors or 3-4 separate experiments. Significance determined by unpaired t-test. 
Figure 3. Production of ROS in primary human monocytes. Primary human monocytes were treated 
with catalase ± MSU crystals for 2 hours (A) or MSU (10 mg/dL) (B) for 6 hours and ROS levels measured 
by ROS-Glo assay. Primary human monocytes were exposed to Pam3 ± MSU or soluble UA for 2 h (C) 
or for 2 h following a 16 h pre-incubation (D) in RPMI or soluble UA. ROS generation was measured 
using the ROS-Glo luminescent based assay from Promega™. Data represent mean of triplicate 
measure from a single donor (A&B) or represent mean values ± S.E.M from 4-6 separate donors (C&D). 
Significance was determined by one-way ANOVA or unpaired t-test. 
Figure 4. Serum UA concentration and stimulation of monocytes from gout patients or healthy 
controls. (A) Uric acid concentration in serum from donors was measured by Amplex red uric acid 
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assay. Monocytes were isolated from whole blood and exposed to Pam3 (B) or Pam3 + MSU crystals 
(C). IL-1β secretion was determined by ELISA. IL-1β secretion in response to MSU was analysed by 
normalisation to secretion induced by Pam3 alone (D). Data represent means from 3-6 repeats for 
each separate donor. Error bars represent average of all donors ± S.E.M. Significance was analysed 
using a two-tail unpaired Mann-whitney test (*P<0.05). 
Figure 5. Expression of NLRP3 inflammasome components in monocytes from gout patients or 
healthy controls. cDNA was prepared from human monocytes, which were isolated from whole blood. 
Expression of CASP1 (A), IL1B (B), NRLP3 (C) and PYCARD (D) was analysed by qPCR. Absolute copy 
numbers were calculated using standard curves for each gene of interest and normalised to expression 
of B2M and RPL32. Each point represents an average of 2-3 replicates. Error bars are derived from 
mean of all samples ± S.E.M. Significance was analysed using a two-tail unpaired Mann-Whitney test 
or by Spearman's correlation coefficient analysis.  
